A case of valproate-induced hyperammonemic encephalopathy: Look beyond the liver

CMAJ. Canadian Medical Association Journal

Volumn 177, Issue 6, 2007, Pages 568-569

  Alqahtani, Saleh ^a   Federico, Paolo ^b   Myers, Robert P ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ETIRACETAM; PHENYTOIN; VALPROIC ACID;

ADULT; ANAMNESIS; BRAIN DISEASE; CASE REPORT; CLINICAL FEATURE; DRUG BLOOD LEVEL; DRUG WITHDRAWAL; ELECTROENCEPHALOGRAPHY; FEMALE; HOSPITAL ADMISSION; HUMAN; HYPERAMMONEMIC ENCEPHALOPATHY; LABORATORY TEST; LIVER; NEUROLOGIC EXAMINATION; PHYSICAL EXAMINATION; SHORT SURVEY; TEMPORAL LOBE EPILEPSY;

EID: 34548801243     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.061272     Document Type: Short Survey

References (6)

1. Hawkes ND, Thomas GA, Jurewicz A, et al. Non-hepatic hyperammonemia: an important, potentially reversible cause of encephalopathy. Postgrad Med J 2001;77:717-22.
2. Segura-Bruna N, Rodriguez-Campello A, Puente V, et al. Valproate-induced hyperammonemic encephalopathy. Acta Neurol Scand 2006;114:1-7.
3. Zaret BS, Beckner RR, Marini AM, et al. Sodium valproate-induced hyperammonemia without clinical hepatic dysfunction. Neurology 1982;32: 206-8.
4. Coulter DL, Allen RJ. Secondary hyperammonaemia: a possible mechanism for valproate encephalopathy. Lancet 1980;1:1310-1.
5. Verrotti A, Trotta D, Morgese G, et al. Valproate-induced hyperammonemic encephalopathy. Metab Brain Dis 2002;17:367-73.
6. Ratnaike RN, Schapel GJ, Rischbieth RH, et al. Hyperammonemia and hepatotoxicity during chronic valproate therapy: enhancement by combination with other antiepileptic drugs. Br J Clin Pharmacol 1986;22:100-3.